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PQUARTERLY FOCUS ISSUE: HEART RHYTHM DISORDERS Viewpoint
Implantable Cardioverter-Defibrillator
Therapy After Acute Myocardial Infarction
The Results Are Not Shocking
Jeffrey J. Goldberger, MD, Rod Passman, MD, MSCE
Chicago, Illinois
The risk of sudden death is highest early after myocardial infarction (MI) and progressively declines over the en-
suing 6 to 12 months. Nevertheless, several randomized clinical trials have failed to show a survival benefit for
implantable cardioverter-defibrillators when implanted early after MI in high-risk patients. The etiology of this
acute MI–sudden cardiac death paradox is unclear, but may be related to the changing nature of the substrate
over the several month period after acute MI. Further investigation is needed to delineate the actual causes of
death in the early post-MI period and which interventions can be implemented to reduce the increased rate of
sudden death that is observed. (J Am Coll Cardiol 2009;54:2001–5) © 2009 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.018R
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tt has been clearly shown in multiple experimental models
nd in clinical practice that myocardial infarction (MI) may
stablish the substrate for fatal ventricular tachyarrhythmias
oth acutely and in the long term. It has also been
ecognized that these arrhythmias may occur either as
rimary events, namely, “reversible” arrhythmias, or as
econdary phenomenon related to actual or impending
echanical failure. With the advent of the coronary care
nit, the immediate identification and defibrillation of these
arly reversible ventricular tachyarrhythmias has resulted in
mportant improvements in survival. However, it has long
een appreciated, and recently confirmed, that the high-risk
eriod for sudden death for patients who survive an acute
I extends beyond the hospitalization period (1,2). Thus,
sing implantable cardioverter-defibrillators (ICDs) in
igh-risk patients early after MI has seemed logical and
mportant. Yet, studies evaluating whether the ICD can
mprove survival after acute MI have failed to show a benefit
or this therapy (3). The acute MI–sudden cardiac death
aradox thus mandates a re-examination of some of our
asic assumptions and a reframing of our approach to better
nderstand the pathophysiology of sudden cardiac death at
his time.
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ccepted August 10, 2009.isk of Sudden Cardiac Death After Acute MI
he risk of sudden death after acute MI has been well
elineated (1). After the index event, typical survival curves
emonstrate a sharp decline initially that plateaus between 6
nd 12 months, with variable risk inversely proportional to left
entricular systolic function. For example, in the VALIANT
Valsartan in Acute Myocardial Infarction) study of 14,609
atients with acute MI and either left ventricular dysfunction
r congestive heart failure randomly assigned to angiotensin
eceptor blocker or an angiotensin-converting enzyme inhibi-
or, or both, the risk of sudden death was highest in the first
onth after MI at 1.4% per month and declined over 2 years
o 0.14% per month. Figure 1 displays the rate of sudden death
r resuscitated cardiac arrest in the VALIANT study stratified
y ejection fraction. In all ejection fraction groups, the inci-
ence of sudden death was highest early after MI and then
apidly declines.
CD Therapy After Acute MI
he preceding data, as well as the documented survival
enefit of the ICD in patients with coronary artery disease
nd left ventricular dysfunction (4–7), provide a convincing
ationale to consider the implementation of ICD therapy
arly after acute MI in high-risk patients. It is interesting to
ote that many of these trials did not enroll patients within
he first 30 days after an acute MI, and the mean time from
he acute MI to enrollment, when documented, was often
ubstantially longer (5–7). DINAMIT (Defibrillators in
cute Myocardial Infarction Trial) evaluated early (within 6
o 40 days of acute MI) ICD placement versus medical
herapy in “high-risk” post-MI patients with left ventricular
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ICDs After MI November 24, 2009:2001–5dysfunction (left ventricular ejec-
tion fraction 35%) and abnor-
malities in autonomic tone as mea-
sured by heart rate or heart rate
variability. There was no difference
in overall mortality (Fig. 2) despite
a high incidence of arrhythmic
vents in both groups (3). With an average follow-up of 30
onths, the annual mortality rate was 7.5% in the ICD group
nd 6.9% in the medical therapy group (p 0.66). Data from
he IRIS (Immediate Risk Stratification Improves Survival)
tudy (8) were recently presented at the 2009 annual sessions of
he American College of Cardiology. In this study, in which
atients were enrolled over a period of 8 years, early (within 5
o 31 days of acute MI) ICD placement was compared with
edical therapy in “high-risk” post-MI patients with left
entricular dysfunction (left ventricular ejection fraction
40%) and resting heart rate90 beats/min, or nonsustained
entricular tachycardia at 150 beats/min. Over a 3-year
ollow-up period, there was no difference in mortality (22.9%
s. 22.0%, p 0.76). These clinical trials have surprised many
linicians and have prompted efforts to explain the failure of
hese trials to demonstrate a benefit of ICD therapy in this
etting.
xplaining the Acute MI–
udden Cardiac Death Paradox
s the risk of sudden death is highest immediately after
cute MI and declines over time, it is a paradox that ICDs
Abbreviations
and Acronyms
ICD  implantable
cardioverter-defibrillator
MI  myocardial infarction
Figure 1 Rates of Sudden Death or Cardiac Arrest
Rates of sudden death or cardiac arrest with resuscitation after acute myocar-
dial infarction, stratified by left ventricular ejection fraction (LVEF). The yellow
line indicates LVEF 30% (n  3,852); the red line indicates LVEF 31% to
40% (n  4,998); and the blue line indicates LVEF 40% (n  2,406).
Reprinted with permission from Solomon et al. (2).beduce mortality only when implanted well after the index
vent despite their near uniform success in successful defi-
rillation of life-threatening ventricular arrhythmias. As-
uming that the data are correct, there appear to be at least
plausible explanations. First, sudden cardiac death is not
ynonymous with an arrhythmic event. It is therefore
ossible that the increased incidence of sudden death that is
oted after acute MI is largely not due to reversible lethal
entricular arrhythmias. If so, an ICD would not be
xpected to have an impact on this type of sudden death.
lternatively, the risk predictors that have been used to
dentify the high-risk population postulated to be suscepti-
le to reversible lethal ventricular arrhythmias may actually
elect for nonarrhythmic causes of death in the early
ost-MI period. It is possible that different risk stratifiers
re necessary to identify patients who will experience revers-
ble ventricular tachyarrhythmias that might benefit from an
CD. Lastly, the act of device implantation and testing may
n some way be deleterious so that whatever potential
enefits ICDs may provide are offset by these negative
ffects. Whether the actual causes of sudden death differ in
he early post-MI period or whether the risk predictors for
dentifying patients susceptible to reversible ventricular
achyarrhythmias differ in the early post-MI period, the
ynamic changes in substrate that occur post-MI may
ccount for these time-dependent changes.
natomic, Ionic, and Neuronal Remodeling
o understand why the pathophysiology of sudden cardiac
eath early post-MI may differ from the pathophysiology of
udden cardiac death later post-MI, it is necessary to
onsider the spectrum of remodeling changes that may
ccur after an acute MI. An understanding of the interplay
Figure 2 Estimates for All-Cause Mortality
Kaplan-Meier estimates for all-cause mortality in the DINAMIT trial (3). ICD 
implantable cardioverter-defibrillator. Reprinted with permission from Hohnloser
et al. (3).etween remodeling and risk for arrhythmias is essential to
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November 24, 2009:2001–5 ICDs After MIhe development of any future insights designed to prevent
atal arrhythmic events in this population.
Alterations in cardiac structure and function induced by
I are responsible for the observed elevations in both acute
nd long-term risks of sudden death after the index event.
ardiac remodeling can be defined clinically in relation to
he changes in ventricular size, shape, and function that
ccur after myocardial injury, pressure, or volume overload.
hese clinical changes are determined at the tissue level
hrough altered genome expression and molecular, cellular,
nd interstitial changes regulated principally by hemody-
amic load and neurohormonal activation.
At the cellular level, myocardial pathologic changes
ccompany left ventricular remodeling and involve myocyte
ypertrophy and fibroblast hyperplasia accompanied by an
ncrease in collagen deposition within the interstitium.
ithin hours of infarction, extracellular matrix is digested
nd results in wall thinning and infarct expansion. In the
eeks after an MI, nonuniform anisotropy results from
ncreases in connective tissue, collagen, and edema between
ells in the epicardial border zone (9). Neurohormonal
gents, local growth-promoting peptides, and physical fac-
ors later result in cardiac hypertrophy. In those persons in
hom these compensatory mechanisms fail to maintain
ardiac output, ventricular dilation begins and heralds the
nset of symptomatic heart failure and its associated
azards (10).
In conjunction with the anatomic changes induced by
I, alterations in ion channels of both infarcted and
oninfarcted tissue cause changes in excitability and repo-
arization that promote re-entry. Peak inward calcium
urrents are reduced in myocytes isolated from the infarcted
order zone regions, and recovery of the fast inward sodium
urrent may also be delayed (11). In areas remote from the
nfarct, cellular hypertrophy can result in prolongation of
ction potential duration and marked heterogeneity in
epolarization times due to reductions in the transient
utward potassium current (12).
On a neuronal level, sympathetic nerve fibers distributed
n perivascular areas and between myocytes of the infarcted
egion may become injured during infarction, and the distal
tumps undergo Wallerian degeneration (13). Afterward,
e-expression of neurotrophic factor genes from around the
ite of injury may trigger regeneration in the axonal sprouts
roximal to the site of injury, possibly in an attempt to
e-establish neuronal control of contractile function (14).
Although the exact mechanism of neuronal remodeling is
nknown, Zhou et al. (15) have demonstrated that infarcted
yocardial cells locally release nerve growth factor and
rowth-associated protein (GAP43), resulting in a cascade
f increased regionalized expression of neurotrophic sub-
tances and their retrograde transport to the left stellate
anglion. The effects at the ganglionic level trigger more
xtensive growth of cardiac sympathetic neurons (15,16).
hen nerve sprouting forms synapses with other fibers,
egional increases in sympathetic hyperinnervation results. hhe exact mechanisms by which denervated regions predis-
ose to arrhythmogenesis is unclear. However, denervation
upersensitivity has been proposed as a possible explanation
hereby myocardial tissue deprived of sympathetic innerva-
ion responds to sympathetic nerve stimulation or norepi-
ephrine infusion with an exaggerated shortening of the
ffective refractory period (17,18). This effect may be
xaggerated in ischemic or infarcted tissue and lead to the
evelopment of ventricular tachyarrhythmias. Whether
hese arrhythmias are as effectively treated by the ICD as
hose due solely to fixed anatomic substrates or other
tiologies has not been established.
Clinically, the time-dependent changes in ventricular
emodeling may occur over a period of years. Gaudron et al.
19) evaluated time-dependent changes in ventricular re-
odeling in patients after acute MI. Over a period of up to
years, there was progressive left ventricular dilation that
as particularly striking among those who died. Further
fforts to understand both the time course of all remodeling
hanges that occur after MI and the factors that determine
hich patients are destined to have the most adverse
emodeling are warranted so that preventive therapies can
e targeted to these patients.
ould Early Post-MI Sudden Death Not Be Due
o Reversible Ventricular Tachyarrhythmias?
n this postulated scenario, there may be 2 periods of risk for
udden cardiac death with different underlying pathophys-
ology: an early period in which ICD therapy is ineffective,
nd a later period in which ICD therapy is effective. The
arly period would be characterized by the ongoing changes
escribed above, and the later period would be characterized
y a fixed substrate resulting from the remodeling. An
mportant study supporting this notion is a retrospective
nalysis of MADIT-II (Multicenter Automatic Defibrilla-
or Implantation Trial II) (20). In this report, there was no
enefit to ICD implantation when used for primary preven-
ion of sudden death in post-MI patients with reduced
jection fractions when the ICD was implanted within 18
onths of the MI. However, there was substantial benefit to
he ICD when implanted 18 months after the MI. Both
he DINAMIT and IRIS studies also support this concept
s there was no ICD benefit even when the patients were
ollowed up to 30 to 36 months. These data support the
otion that there may be an extended period of time on the
rder of at least 1 to 2 years after MI in which an ICD may
ot improve survival, at least under the current implant
ndications.
Further support for a different pathophysiology for sud-
en death in the early post-MI period derives from the
PHESUS (Eplerenone Post-Acute Myocardial Infarction
eart Failure Efficacy and Survival Study) investigators
21). They demonstrated that eplerenone, a selective al-
osterone blocker with numerous properties including in-
ibition of ventricular remodeling and collagen deposition,
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ICDs After MI November 24, 2009:2001–5ecreased the overall risk of sudden cardiac death by 21%
hen given to patients with acute MI complicated by left
entricular dysfunction and heart failure (21). Further anal-
sis of the data reported a 37% reduction in sudden cardiac
eath within 30 days of randomization for enrollees with an
jection fraction 40% and a 58% reduction if the ejection
raction was 30% (22). In sum, these findings support the
oncept that in the early post-MI period, treatments aimed
t affecting remodeling impact sudden death whereas treat-
ents focused solely on treating the arrhythmias once they
ccur appear ineffective.
re Different Risk Predictors Needed in the Early
ost-MI Period to Identify Patients Who Will
xperience Reversible Ventricular Tachyarrhythmias?
n alternative explanation for the lack of ICD benefit
bserved early after an MI is that the selection criteria for
dentifying patients at risk for treatable ventricular tachyar-
hythmias may need to be different in the early post-MI
eriod in which active remodeling is ongoing. There are no
ata that firmly support this contention. However, the
ESTICD (Beta-Blocker Strategy Plus ICD) trial (23)
rovides some interesting insights. This trial was terminated
rematurely because of poor enrollment. Patients within 5
o 30 days of an acute MI with an ejection fraction 35%
nd either 10 premature ventricular complexes per hour,
epressed heart rate variability, or a positive signal-averaged
lectrocardiogram were randomly allocated to standard
edical therapy (n  59) or to an electrophysiology study-
uided ICD strategy (n  79). Only patients with inducible
entricular tachycardia received an ICD. Although the trial
as negative, the reported 1- and 2-year mortality rates in
he standard medical therapy group were 18% and 29.5%
ersus 11% (p  0.3) and 20% (p  0.2) for the electro-
hysiology study guided ICD strategy group. However,
hese differences were not statistically significant, and the
tudy was too small to make firm conclusions. Despite this
imitation, it is interesting to note that the use of a
isk-stratification tool that should be fairly specific for
entricular tachyarrhythmias, namely, electrophysiologic
esting, was associated with some difference, albeit not
tatistically significant, in outcome.
In the REFINE (Risk Estimation Following Infarction,
on-invasive Evaluation) study, Exner et al. (24) employed
combined assessment of autonomic tone plus cardiac
lectrical substrate in an attempt to identify both a high-risk
opulation after acute MI and the optimal timing of risk
valuation. While impaired heart rate turbulence plus ab-
ormal T-wave alternans measured at 10 to 14 weeks after
I best identified patients at high risk for cardiac death or
ardiac arrest, no single variable or combination of variables
as useful at predicting future cardiac events when mea-
ured at 2 to 4 weeks post-infarction. In sum, these studies
rovide further evidence that the electrophysiologic milieu
hanges with time after an acute MI and that both thessessment of risk and the treatments exhibit a degree of
ime-dependency previously unappreciated.
an ICD Implantation/Testing Early Post-MI
e Associated With Deleterious Effects?
everal recent studies have suggested that clinical ICD
hocks, whether appropriate or inappropriate, may be asso-
iated with poor subsequent survival (25–27). While there
re many potential explanations for this finding, it is
ertainly feasible that some patients may be susceptible to
eleterious effects of a high-voltage shock. High-voltage
hocks have been associated with electroporation manifest
y local repolarization changes (28), transient myocardial
ysfunction (29), and potential for troponin release/
levation (30). Whether these potentially deleterious effects
f an ICD shock occur with greater frequency in the setting
f a healing versus healed MI has not been studied. This
otential interaction between shocks and time from MI
erits further investigation.
onclusions
he acute MI–sudden cardiac death paradox has now been
rmly established. Given the demonstrated efficacy of ICDs
n terminating ventricular tachyarrhythmias, it seems most
ompelling that sudden cardiac death early post-MI may
ot be due to arrhythmia alone. However, it is possible that
nique risk predictors are needed to identify those patients
t risk for primary arrhythmic death post-MI. Finally, a
otential deleterious effect of ICD implantation and testing
uring this period also deserves further exploration.
Once these issues have been clarified, it may be possible to
eassess which therapies and which risk predictors should be
tudied in the dynamic milieu of the early post-MI substrate.
etter understanding of these changes and how risk changes
ver time both quantitatively and qualitatively is a challenging
ndeavor that is necessary if the goal is to further reduce
ortality during this high-risk period.
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